Opus Genetics (IRD) Share-based Compensation (2010 - 2026)

Opus Genetics (IRD) has 17 years of Share-based Compensation data on file, last reported at $1.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 60.35% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $8.8 million, a 81.07% increase from a year earlier, with the FY2025 full-year figure at $5.7 million, down 6.56% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.5 million, down from $3.3 million in the prior quarter.
• Over the last five years, Share-based Compensation for IRD reached as high as $6.1 million in Q2 2025 and fell as low as $445000.0 in Q1 2022.
• Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $913000.0 in 2025.
• Across the five-year window, Share-based Compensation jumped 1796.15% in 2022 and plunged 43.32% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $493000.0 in 2022, then soared by 44.22% to $711000.0 in 2023, then soared by 344.73% to $3.2 million in 2024, then climbed by 4.33% to $3.3 million in 2025, then slumped by 55.62% to $1.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.5 million in Q1 2026, $3.3 million in Q4 2025, and $6.0 million in Q3 2025.